

**Renal disease:
update searches and screening
for
Universitätsklinikum Schleswig-Holstein/Campus Kiel**



Kleijnen Systematic Reviews Ltd

November 2021

Kleijnen Systematic Reviews Ltd
Unit 6, Escrick Business Park
Riccall Road
Escrick
York
YO19 6FD
United Kingdom
Telephone: +44 (0)1904 727980
Fax: +44 (0)1904 720429
Email: robert@systematic-reviews.com
Website: www.systematic-reviews.com

Pawel Posadzki
Adrian Hernandez
Steven Duffy
Jos Kleijnen
Robert Wolff

1. PROJECT OBJECTIVES

A key aim of the research project “Making SDM a reality” is to inform patients as part of shared decision making (SDM).

Kleijnen Systematic Reviews (KSR) Ltd has prepared an evidence report with a synthesis of the evidence of the treatment options for renal disease.

2. METHODS

LITERATURE SEARCHES

Literature searches were conducted to identify systematic reviews and evidence-based guidelines about end-stage renal disease to update the 2018 evidence report.

The search strategies were developed specifically for each database and the keywords adapted according to the configuration of each database. Searches were limited by date range for systematic reviews and guidelines to 2018-2021. Searches were not limited by language or publication status.

Systematic reviews and guidelines

The following systematic review and health technology assessment specific databases were searched:

- Cochrane Database of Systematic Reviews (CDSR) (Wiley): Issue 9 of 12, September 2021
- KSR Evidence (Internet) (<https://ksrevidence.com/>): 2018-20.9.21
- Epistemonikos (Internet) (<https://www.epistemonikos.org/>): 2018-20.9.21
- International HTA Database (INAHTA) (<https://database.inahta.org/>): 2018-20.9.21

The following guidelines resources were searched:

- Guidelines International Network (GIN) (Internet) (<https://www.g-i-n.net/home>): up to 2018-20.9.21
- NICE Evidence (Internet) (www.evidence.nhs.uk/): 2018-20.9.21
- NICE Guidance (Internet) (<https://www.nice.org.uk/guidance>): 2018-20.9.21
- ECRI Guidelines Trust (Internet) (<https://guidelines.ecri.org/>): 2018-20.9.21
- Trip Database (<https://www.tripdatabase.com/>): 2018-20.9.21
- Canadian Agency for Drugs and Technologies in Health (CADTH) (www.cadth.ca): 2018-20.9.21

Full details of all search strategies are presented in Appendix 1.

Handling of citations

References identified from the searches were downloaded into EndNote bibliographic management software for further assessment and handling.

Supplementary searches

The bibliographies of included studies and review articles were also checked for additional relevant articles.

Prioritisation

During formal screening of titles and abstracts, studies were subject to a prioritisation process whereby the recency e.g., to most up-to-date clinical practice guidelines (CPG), methodological quality e.g., Cochrane systematic review (CSR), quality of the analyses per outcome (e.g., ratio of RCTs to observational studies), the number of included RCTs, the breadth of the timepoints reported etc. were considered to further prioritise which studies would be used to inform analyses. Studies were categorised into the following three categories: '1' = German, American, European or similar CPG; '2' = CSR or similar quality SR; '3' = potentially lower/other quality SR.

3. RESULTS

The original KSR searches were conducted on February 22, 2018; and of the 2540 references screened, 11 studies were deemed eligible. In the current update, a total of 1705 records were retrieved from the electronic literature searches (see Appendix 1). After the removal of duplicate records, 1149 titles and abstracts were screened by two reviewers. Twenty-four records were found to be potentially eligible and were longlisted after a consensus. Of those, five were short-listed and included in the analyses (Table 1).¹⁻⁵ See also Table 2 for an overview of primary studies included in the identified SRs/CPGs.

UPDATE – Concluding Assessment by SHARE-TO-CARE Evidence Team (26/08/22)

Based on the update searches conducted by KSR Ltd in September 2021, we want to highlight the following aspects: the four recently published clinical practice guidelines (NICE, 2018; Ashby et al., 2019; BTS, 2018; MCKDWG, 2019) as well as the HTA report (CADTH, 2018) are in line with the current version of the decision aid, while the paucity of convincing data comparing quality of life outcomes between ESRD treatment modalities persists.

Conclusion regarding the evidence report: No evidence update required. The present evidence report (June, 2018) remains valid until further notice.

Table 1 Evidence sources

Study/year	Evidence type	Primary studies	Number of studies	Intervention	Comparator	Outcome	Date searched	Conclusions
NICE 2018 ¹	CPG	RCTs	42	Transplant; Peritoneal dialysis; Haemodialysis; Conservative management	Various	Multiple	December, 11, 2017	See section 1.4.3
Ashby 2019 ²	CPG	RCTs	6*	Haemodialysis	Various	Multiple	June 2018	See section 2.
BTS ³	CPG	SRs, RCTs	5*	Transplant	Various	Multiple	November 1, 2016	See sections 5.8.6; 5.10.5 and 11
CADTH 2018 ⁴	HTA	SRs, RCTs	40	Dialysis (various)	Various	Multiple	June 3, 2016	"[...] overall, home-based modalities appear to offer clinical benefits similar to self-care in-centre haemodialysis. No consistent differences in patient health-related quality of life outcomes between home haemodialysis and in-centre haemodialysis or peritoneal dialysis and in-centre haemodialysis were identified, and there is no clear evidence of a survival benefit with any specific dialysis modality"
MCKDWG 2019 ⁵	CPG	SRs, RCTs, non-RCTs, OS	105	Various	Various	Multiple	November 2018	See section VI, subsections B,C,D,E

* = only studies published after 2010 were extracted

BTS = British Transplantation Society; CADTH = Canadian Agency for Drugs and Technologies in Health; CGP = clinical practice guideline; CR = case report; CS = case series; HTA = health technology assessment; MCKDWG = The Management of Chronic Kidney Disease Work Group; NICE = National Institute for Health and Care Excellence; OS = observational study; RCT = randomised controlled trial; CSR = Cochrane systematic review.

Table 2 Overview of primary studies included in the identified SRs/CPGs

Study/year	Primary study(ies)	Reference (first author & journal)
NICE 2018 ¹	RCTs*	1. Amaral S, Sayed BA, Kutner N, Patzer RE. Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease. <i>Kidney International</i>. 2016; 90(5):1100-1108 2. Balasubramanian G, McKitty K, Fan SL. Comparing automated peritoneal dialysis with continuous ambulatory peritoneal dialysis: survival and quality of life differences? <i>Nephrology Dialysis Transplantation</i>. 2011; 26(5):1702-8 3. Beduschi Gde C, Figueiredo AE, Olandoski M, Pecoits-Filho R, Barretti P, de Moraes TP et al. Automated peritoneal dialysis is associated with better survival rates compared to continuous ambulatory peritoneal dialysis: A propensity score matching analysis. <i>PloS One</i>. 2015; 10(7):e0134047 4. Chandna SM, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K. Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. <i>Nephrology Dialysis Transplantation</i>. 2011; 26(5):1608-14 5. Chertow GM, Levin NW, Beck GJ, Daugirdas JT, Eggers PW, Kliger AS et al. Longterm effects of frequent in-center hemodialysis. <i>Journal of the American Society of Nephrology</i>. 2016; 27(6):1830-6 6. den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Mazairac AH, Penne EL et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. <i>Kidney International</i>. 2014; 86(2):423-32 7. den Hoedt CH, Grooteman MP, Bots ML, Blankestijn PJ, van der Tweel I, van der Weerd NC et al. The effect of online hemodiafiltration on infections: Results from the CONvective TRANsport STudy. <i>PloS One</i>. 2015; 10(8):e0135908 8. Grams ME, Po-Han BC, Coresh J, Segev DL. Preemptive deceased donor kidney transplantation: Considerations of equity and utility. <i>Clinical Journal of the American Society of Nephrology</i>. 2013; 8(4):575-582 9. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. <i>Journal of the American Society of Nephrology</i>. 2012; 23(6):1087-96 10. Hall YN, Larive B, Painter P, Kaysen GA, Lindsay RM, Nissenson AR et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. <i>Clinical Journal of the American Society of Nephrology</i>. 2012; 7(5):782-94 11. Kantartzi K, Panagoutsos S, Mourvati E, Roumeliotis A, Leivaditis K, Devetzi V et al. Can dialysis modality influence quality of life in chronic hemodialysis patients? Lowflux hemodialysis versus high-flux hemodiafiltration: a cross-over study. <i>Renal Failure</i>. 2013; 35(2):216-21

Study/year	Primary study(ies)	Reference (first author & journal)
		12. Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. <i>Journal of the American Society of Nephrology</i>. 2013; 25(3):587-594 13. Kurella Tamura M, Unruh ML, Nissenson AR, Larive B, Eggers PW, Gassman J et al. Effect of more frequent hemodialysis on cognitive function in the frequent hemodialysis network trials. <i>American Journal of Kidney Diseases</i>. 2013; 61(2):228- 37 14. Lafrance JP, Rahme E, Iqbal S, Elftouh N, Vallee M, Laurin LP et al. Association of dialysis modality with risk for infection-related hospitalization: a propensity scorematched cohort analysis. <i>Clinical Journal of the American Society of Nephrology</i>. 2012; 7(10):1598-605 15. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J et al. Highefficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. <i>Journal of the American Society of Nephrology</i>. 2013; 24(3):487-97 16. Mazairac AH, Blankestijn PJ, Grooteman MP, Lars Penne E, van der Weerd NC, den Hoedt CH et al. The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. <i>Nephrology Dialysis Transplantation</i>. 2013; 28(7):1865- 1873 17. Mesaros-Devicic I, Tomljanovic I, Mikolasevic I, Dvornik S, Vujicic B, Pavletic-Persic M et al. Survival of patients treated with online hemodiafiltration compared to conventional hemodialysis. <i>Collegium Antropologicum</i>. 2013; 37(3):827-32 18. Morena M, Jaussent A, Chalabi L, Leray-Moragues H, Chenine L, Debure A et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. <i>Kidney International</i>. 2017; 91(6):1495-1509 19. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. <i>Nephrology Dialysis Transplantation</i>. 2013; 28(1):192-202 20. Pavlakis M. The timing of dialysis and kidney transplantation in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i>. 2012; 14(8):689-693 21. Rocco MV, Daugirdas JT, Greene T, Lockridge RS, Chan C, Pierratos A et al. Longterm effects of frequent nocturnal hemodialysis on mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. <i>American Journal of Kidney Diseases</i>. 2015; 66(3):459-68

Study/year	Primary study(ies)	Reference (first author & journal)
		22. Rocco MV, Lockridge RS, Jr., Beck GJ, Eggers PW, Gassman JJ, Greene T et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. <i>Kidney International</i>. 2011; 80(10):1080-91 23. Stefansson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. <i>Nephron Extra</i>. 2012; 2(1):55-65 24. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH et al. Risk of vascular access complications with frequent hemodialysis. <i>Journal of the American Society of Nephrology</i>. 2013; 24(3):498-505 25. Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J et al. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials. <i>American Journal of Kidney Diseases</i>. 2013; 61(5):748-58 26. Yeates K, Zhu N, Vonesh E, Trpeski L, Blake P, Fenton S. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. <i>Nephrology Dialysis Transplantation</i>. 2012; 27(9):3568-75
Ashby 2019 ²	RCTs*	1. Locatelli F, et al. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial. <i>Nephrol Dial Transplant</i>. 2014 Jun;29(6):1239-46. 2. Leung KCW et al, Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis <i>Clin J Am Soc Nephrol</i>. 2017 Nov 7;12(11):1831-1840 3. Hur E., et al., Effect of Fluid Management Guided by Bioimpedance Spectroscopy on Cardiovascular Parameters in Hemodialysis Patients: A Randomized Controlled Trial. <i>AJKD</i> 2013, 61(6): 957-965 4. Dhondt A, Pauwels R, Devreese K, Eloot S, Glorieux G, Vanholder R. Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial. <i>PLoS One</i>. 2015;10(6):e0128634. doi: 10.1371 5. Guéry B, Alberti C, Servais A, Harrami E, Bererhi L, Zins B, Touam M, Joly D. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. <i>PLoS One</i>. 2014;9(5): e97187 6. Elliott J, Rankin D, Jacques RM, Lawton J, Emery CJ, Campbell MJ, et al. A cluster randomized controlled non-inferiority trial of 5-day Dose Adjustment for Normal Eating (DAFNE) training delivered over 1 week versus 5-day DAFNE training delivered over 5 weeks: the DAFNE 5 x 1-day trial. <i>Diabet Med</i>. 2015;32(3):391-8

Study/year	Primary study(ies)	Reference (first author & journal)
BTS ³	SRs, RCTs*	1. Ahmed Z, Uwechue R, Kessar N, Mamode N. Prophylaxis of wound infections - antibiotics in renal donation (POWAR): a multicentre UK double blinded placebo controlled randomised controlled trial. American Transplant Congress. (abstract) 2018. 2. Awad S, Varadhan KK, Ljunqvist O, Lobo DN.. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clin Nutr 2013; 32: 34-44. 3. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256: 18-24. 4. Lafranca JA, Hagan SM, Dols LF, et al. Systematic review and meta-analysis of the relation between donor body mass index and short-term donor outcome of laparoscopic donor nephrectomy. Kidney Int 2013; 83: 931-9. 5. Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant 2013; 13: 2645-52.
CADTH 2018 ⁴	SRs, RCTs	See appendix 3 of the CADTH report.
MCKDWG 2019 ⁵	SRs, RCTs	1. Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrastinduced nephropathy: A meta-analysis of 15 randomized controlled trials. Medicine (Baltimore). Jul 2017;96(27):e7384 2. Solomon R, Gordon P, Manoukian SV, et al. Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol. Sep 4 2015;10(9):1519-1524 3. Luo Y, Wang X, Ye Z, et al. Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with st-segment elevation myocardial infarction: A single-center, randomized trial. Intern Med. 2014;53(20):2265-2272. 4. Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am J Kidney Dis. Dec 2018;72(6):798-810. 5. Mukri MNA, Kong WY, Mustafar R, et al. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial. EXCLI J. 2018;17:563-575 6. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis. Jan 2012;59(1):58-66 7. Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. Sep 5 2014;9(9):1620-1626

Study/year	Primary study(ies)	Reference (first author & journal)
		8. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. <i>JAMA</i>. Feb 15 2012;307(7):674-684 9. Villar E, Lievre M, Kessler M, et al. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: Results of the NEPHRODIAB2 randomized trial. <i>J Diabetes Complications</i>. Jul-Aug 2011;25(4):237- 243. 10. Patel M, Thimons DG, Winston JL, Langholff W, McGowan T. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. <i>J Am Med Dir Assoc</i>. Mar 2012;13(3):244-248. 11. Akizawa T, Gejyo F, Nishi S, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: A randomized controlled study. <i>Ther Apher Dial</i>. Oct 2011;15(5):431-440. 12. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. <i>Nephrol Dial Transplant</i>. Nov 2014;29(11):2075-2084 13. Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. <i>Am J Kidney Dis</i>. Feb 2013;61(2):211-218 14. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. <i>J Am Soc Nephrol</i>. Dec 2013;24(12):2096-2103 15. Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: A cluster-randomized trial. <i>PLoS One</i>. 2016;11(3):e0151422. 16. Joboshi H, Oka M. Effectiveness of an educational intervention (the Encourage Autonomous Self-Enrichment Program) in patients with chronic kidney disease: A randomized controlled trial. <i>Int J Nurs Stud</i>. Feb 2017;67:51-58. 17. Valentijn PP, Pereira FA, Ruospo M, et al. Person-centered integrated care for chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. <i>Clin J Am Soc Nephrol</i>. Mar 7 2018;13(3):375-386.
* = only studies published after 2010 were extracted BTS = British Transplantation Society; CADTH = Canadian Agency for Drugs and Technologies in Health; MCGDWG = The Management of Chronic Kidney Disease Work Group; NICE = National Institute for Health and Care Excellence; RCT = randomised controlled trial; SR = Cochrane systematic review.		

REFERENCES

- [1] National Institute for Health and Care Excellence. *Renal replacement therapy and conservative management. NICE guideline [NG107] [Internet]*. London: NICE, 2018 [accessed 20.9.21] Available from: <https://www.nice.org.uk/guidance/ng107>
- [2] Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, et al. *Clinical practice guideline: Haemodialysis*: Renal Association, 2019. 74p. Available from: <https://renal.org/sites/renal.org/files/FINAL-HD-Guideline.pdf>
- [3] British Transplantation Society, Renal Association. *Guidelines for living donor kidney transplantation. 4th edition*: British Transplantation Society; Renal Association, 2018. 295p. Available from: <https://renal.org/sites/renal.org/files/Living-Donor.pdf>
- [4] Canadian Agency for Drugs and Technologies in Health (CADTH). *Dialysis modalities for the treatment of end-stage kidney disease [Internet]*. Ottawa: CADTH, 2018 [accessed 20.9.21] Available from: <https://www.cadth.ca/dialysis-modalities-treatment-end-stage-kidney-disease-0>
- [5] The Management of Chronic Kidney Disease Working Group. *VA/DoD clinical practice guideline for the management of chronic kidney disease. Version 4.0*. Washington (DC): Department of Veterans Affairs, Department of Defense, 2019. 159p. Available from: <https://guidelines.ecri.org/profile/15>

APPENDIX 1: SEARCH STRATEGIES

Shared Decision Making: Renal disease update (KSR)

Table 3. Systematic reviews and guideline search results

Database	Dates	Results
CDSR	2018 - Iss 9/12 Sept 2021	54
KSR Evidence	2018-20.9.21	567
Epistemonikos	2018-20.9.21	592
INAHTA	2018-20.9.21	11
NICE Evidence	2018-20.9.21	381
NICE Guidance	2018-20.9.21	18
GIN	2018-20.9.21	0
ECRI	2018-20.9.21	41
Trip	2018-20.9.21	22
CADTH	2018-20.9.21	19
Total		1705
Total after de-duplication		1149
Total after de-duplication with original ENL		1140

Search strategies

Cochrane Database of Systematic Reviews (CDSR) (Wiley): Issue 9 of 12, September 2021

Date searched: 20.9.21

Records found: 54

- #1 MeSH descriptor: [Kidney Failure, Chronic] explode all trees 4804
- #2 ((Chronic or end-stage or end stage or "stage 5" or "stage five") near/2 (renal or kidney*) near/2 (failure* or disease* or disorder* or insufficien* or dysfunction)):ti,ab,kw18013
- #3 #1 or #2 with Cochrane Library publication date Between Jan 2018 and Sep 2021, in Cochrane Reviews, Cochrane Protocols 54

CDSR Reviews = 42

CDSR Protocols = 12

KSR Evidence: 2018 – 20.9.21

<https://ksrevidence.com/>

Date searched: 20.9.21

Records found: 567

- 1 (Chronic or "end-stage" or "end stage" or "stage 5" or "stage five") near/2 (renal or kidney*) near/2 (failure* or disease* or disorder* or insufficien* or dysfunction) in Title 819 results
 - 2 (Chronic or "end-stage" or "end stage" or "stage 5" or "stage five") near/2 (renal or kidney*) near/2 (failure* or disease* or disorder* or insufficien* or dysfunction) in Bottom line 88 results
 - 3 #1 or #2 in All text 567 results
- Filtered by: PUBLICATION DATE 2022, 2021, 2020, 2019, 2018

Epistemonikos: 2018-20.9.21

<https://www.epistemonikos.org/>

Date searched: 20.9.21

Records found: 592

title:("End stage renal" OR "end stage kidney" OR "stage 5 renal" OR "stage 5 kidney" OR "stage five renal" OR "stage five kidney" OR "chronic renal" OR "chronic kidney")

Limits:

Publication year: 2018-2021

Publication type: Systematic review

Cochrane review: no

International HTA Database: 2018-20.9.21

<https://database.inahta.org/>

Date searched: 20.9.21

Records found: 11

- 4 #3 OR #2 OR #1 118

3 ("End stage renal" OR "end stage kidney" OR "stage 5 renal" OR "stage 5 kidney" OR "stage five renal" OR "stage five kidney" OR "chronic renal" OR "chronic kidney")[abs]
 2 ("End stage renal" OR "end stage kidney" OR "stage 5 renal" OR "stage 5 kidney" OR "stage five renal" OR "stage five kidney" OR "chronic renal" OR "chronic kidney")[Title] 55
 1 "Kidney Failure, Chronic"[mhe] 45

Limits:

Publication year: 2018-2022

NHS Evidence: 2018-20.9.21

<https://www.evidence.nhs.uk/>

Date searched: 20.9.21

Records found: 381

"End stage renal" OR "end stage kidney" OR "stage 5 renal" OR "stage 5 kidney" OR "stage five renal" OR "stage five kidney" OR "chronic renal" OR "chronic kidney"

Limits:

Evidence type: Guidance

Publication year: 2018-2021

NICE Guidance (Internet): 2018-20.9.21

<https://www.nice.org.uk/guidance>

Date searched 20.9.21

Records found: 18

Search terms	Results (2018+)
kidney	7
renal	11
Total retrieved	18

Limits:

Type: guidance

Last updated: 01/2018 – 09.2021

International Guideline Library (GIN): 2018-20.9.21

<https://g-i-n.net/>

Date searched 20.9.21

Records found: 0

Search terms	Results (2018+)
renal	0

kidney	0
Total retrieved	0

Limits:

Last updated: 2018 - 2021

ECRI Guidelines Trust: 2018-20.9.21

<https://guidelines.ecri.org/>

Date searched 20.9.21

Records found: 41

Search terms	Results
Chronic renal	11
Chronic kidney	16
End stage renal	6
End stage kidney	6
Stage five renal	1
Stage five kidney	1
Total retrieved	41

Limits:

Publication year: 2018 - 2021

Trip Database: 2018-20.9.21

<https://www.tripdatabase.com/>

Date searched 20.9.21

Records found: 22

Title = "chronic renal" OR "chronic kidney" OR "end stage renal" OR "end stage kidney" OR "stage five renal" OR "stage five kidney"

Limits:

Guidelines

2018+

Canadian Agency for Drugs and Technologies in Health (CADTH) (Internet): 2018-20.9.21

<https://www.cadth.ca/health-technology-review>

Date searched: 20.9.21

Records found: 19

Search terms	Results
Chronic renal	5
Chronic kidney	4
End stage renal	4
End stage kidney	4

Stage five renal	1
Stage five kidney	1
Total retrieved	19

Limits:

Project line: Health Technology Review

Last updated: 01/01/2018